Cholangiocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | FGFR2::v | Cholangiocarcinoma | Infigratinib | |
| FDA (1) HC (1) | IDH1 p.R132C | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) HC (1) | IDH1 p.R132G | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) HC (1) | IDH1 p.R132H | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) HC (1) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) HC (1) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib | |
| FDA (1) HC (1) | FGFR2::v | Cholangiocarcinoma | Pemigatinib | |
| FDA (1) HC (1) | FGFR2 rearrangements | Cholangiocarcinoma | Pemigatinib | |
| FDA (1) | HER2-positive | Cholangiocarcinoma | Zanidatamab |